Influence of Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype on Clinical Outcomes and Pharmacokinetics in Chinese Patients With Metastatic Colorectal Cancer

Trial Profile

Influence of Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype on Clinical Outcomes and Pharmacokinetics in Chinese Patients With Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 29 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 27 Feb 2013 Planned number of patients changed from 50 to 500 as reported by ClinicalTrials.gov.
    • 02 May 2012 Planned end date changed from 1 May 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top